Products for Research Use Only
RegisterLogin

AZD3229

CAT: 0013-GTR19162891-01Size: 200 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0013-GTR19162891-01Size:200 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
AZD3229 (AZD-3229) is a potent, pan-KIT mutant inhibitor with potent single digit nM growth inhibition against a diverse panel of mutant KIT driven Ba/F3 cell lines (GI50=1-50 nM) ; shows good margin to KDR-driven effects, also inhibits PDGFR mutants (Tel-PDGFRα, Tel-PDGFRβ, V561D/D842V) .
CAS Number
2248003-60-1
Product Name Alternative
AZD-3229 | AZD 3229
Purity
>98% (HPLC)
Solubility
DMSO: 95 mg/mL (198.12 mM) ; Water: Insoluble (< 1 mg/ml refers to the product slightly soluble or insoluble)
Smiles
O=C (NC1=CC=C (NC2=C3C (F) =CC (OCCOC) =CC3=NC=N2) C=C1) CN4N=NC (C (C) C) =C4
Molecular Formula
C24H26FN7O3
Molecular Weight
479.516
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
N- (4-{[5-Fluoro-7- (2-methoxyethoxy) quinazolin-4-yl]-amino}phenyl) -2-[4- (propan-2-yl) -1H-1,2,3-triazol-1-yl]-acetamide

Chemical Information

Ubavitinib

Ubavitinib is an orally bioavailable inhibitor of specific mutated forms of platelet-derived growth factor receptor alpha (PDGFR alpha; PDGFRa) and mast/stem cell factor receptor c-Kit (SCFR; CD117), with potential antineoplastic activity. Upon oral administration, ubavitinib specifically targets, binds to and inhibits specific mutant forms of PDGFRa and c-Kit. This results in the inhibition of PDGFRa- and c-Kit-mediated signal transduction pathways and the inhibition of proliferation in tumor cells that express these PDGFRa and c-Kit mutants. PDGFRa and c-Kit, protein tyrosine kinases, are upregulated or mutated in various tumor cell types; they play key roles in the regulation of cellular proliferation and resistance to chemotherapy.

CAS Number2248003-60-1
PubChem CID134814269
IUPAC NameN-[4-[[5-fluoro-7-(2-methoxyethoxy)quinazolin-4-yl]amino]phenyl]-2-(4-propan-2-yltriazol-1-yl)acetamide
Molecular FormulaC24H26FN7O3
Molecular Weight479.5
XLogP3.3
Topological Polar Surface Area116
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count9
Rotatable Bond Count10
Heavy Atom Count35
Formal Charge0
Complexity667
SMILES
CC(C)C1=CN(N=N1)CC(=O)NC2=CC=C(C=C2)NC3=NC=NC4=C3C(=CC(=C4)OCCOC)F
InChI
InChI=1S/C24H26FN7O3/c1-15(2)21-12-32(31-30-21)13-22(33)28-16-4-6-17(7-5-16)29-24-23-19(25)10-18(35-9-8-34-3)11-20(23)26-14-27-24/h4-7,10-12,14-15H,8-9,13H2,1-3H3,(H,28,33)(H,26,27,29)
InChIKey
FLJOFQUXYAWOPE-UHFFFAOYSA-N
Chemical Structure
2D Structure
2D structure of Ubavitinib
CAS: 2248003-60-1
CID: 134814269
Formula: C24H26FN7O3
MW: 479.5
Interactive 3D Structure
Loading 3D structure...
View on PubChemRaw 3D data
Computed Properties
PropertyValue
Molecular Weight479.5
XLogP33.3
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count9
Rotatable Bond Count10
Exact Mass479.20811588
Monoisotopic Mass479.20811588
Topological Polar Surface Area116 Ų
Heavy Atom Count35
Formal Charge0
Complexity667
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently-Bonded Unit Count1
Compound Is CanonicalizedYes

Related Products

CatalogName
GTR19259418-01AZD2389
GTR19258720-01AZD2389
GTR19203982-01AZD8329
GTR19168096-01AZD3264
GTR19162987-01AZD3264
GTR19169003-01AZD3759 hydrochloride
GTR19168095-01AZD3839 free base

Alternative Products

CatalogName
YPD00360-01AZD3229
T71894-01AZD3229 Tosylate
A19259-50AZD3229 50mg
A19259-10AZD3229 10mg
A19259-200AZD3229 200mg

Popular Products